Strategic Diagnostics Announces Success in Demonstrating Utility of its Proprietary Genomic Antibodies™ Reagents on Clinical Samples in Cooperation with the Human Protein Atlas
NEWARK, Del., April 30, 2007 - Strategic Diagnostics Inc. (Nasdaq: SDIX) today announced the successful
use of a number of its antibody reagents on clinical samples in studies being conducted by the Swedish Human
Protein Atlas (HPA) program of the Human Proteome Resource (HPR) Center located in Stockholm, Sweden. The
reagents, produced using SDI's proprietary Genomic Antibody Technology™, specifically target a selection of
cancer associated proteins. The antibodies were studied in the HPA's tissue-profiling program and generated high resolution
immunohistochemistry images across a wide spectrum of normal and cancerous tissues. Analyses of
immunohistochemistry images are standard tests performed by pathology laboratories to diagnose disease. For each
antibody, 576 spots of human tissue from 360 different individuals were treated and stained.
Images created in the analysis clearly demonstrated the ability of antibodies generated by SDI's high throughput
Genomic Antibody Technology™ to differentially stain cancer-associated proteins in patient tissue samples. The
antibodies are created by using a proprietary system that produces recombinant protein inside the host animal,
thereby activating an immune response to the encoded protein. This allows the production of antibodies generated
against the protein's native structure, rather than traditional methods that produce antibodies to synthesized
surrogates. Among the advantages of the Genomic Antibody Technology™ is its ability to enable the development
of reagents against traditionally difficult cellular targets, such as highly conserved and transmembrane proteins. The
system is highly scaleable, allowing the generation of custom libraries consisting of hundreds of antibodies for use in
the drug discovery, diagnostic, and research markets. SDI is currently developing a significant number of these
innovative reagents to be offered via a web-based catalog.
Matthew H. Knight, the Company's President and Chief Executive Officer, commented, "The demonstrated
advantages of our Genomic Antibody Technology™ continue to produce real-world data to differentiate our
antibody reagents from antibody reagents generated by traditional means. The HPA data is more evidence that our
antibodies can perform under rigorous study conditions."
Strategic Diagnostics offers custom service access to its Genomic Antibody Technology™ for polyclonal and
monoclonal products.
About Strategic Diagnostics Inc.
Strategic Diagnostics Inc. is a leading provider of antibody technology to the Life Science
market place. Additionally the company provides biotechnology-based detection solutions
for a broad range of food, water, agricultural, and environmental applications. By applying its
core competencies of antibody and assay development, the Company produces unique,
sophisticated reagents, reagent systems, antibody design services and bio-detection solutions
to customer needs. Customers benefit from the enablement of their research into critical
health care challenges of disease understanding, therapeutic development and diagnostic
discovery. Industrial customers benefit with quantifiable "return on investment" by
reducing time, labor, and/or material costs. All this is accomplished while increasing
accuracy, reliability and actionability of essential test results. The Company is focused on
sustaining this competitive advantage by leveraging its expertise in antibody design,
immunology, proteomics, bio-luminescence and other bio-reactive technologies to continue
its successful customer-focused research and development efforts. Recent innovations in
high throughput production of antibodies from genetic antigens will complement the
Company's established leadership in commercial and custom antibody production for the
Research, Human/Animal Diagnostics, and Pharmaceutical industries, and position the
Company for broader participation in proteomics research and discovery.
This news release contains forward-looking statements reflecting SDI's current expectations. When used in this press release, the words "anticipate",
"could", "enable", "estimate", "intend", "expect", "believe", "potential", "will", "should", "project", "plan" and similar expressions as they relate to
SDI are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and
uncertainties, which may cause actual results to differ from those anticipated by SDI at this time. Such risks and uncertainties include, without
limitation, changes in demand for products, delays in product development, delays in market acceptance of new products, retention of customers and
employees, adequate supply of raw materials, the successful integration and consolidation of the Maine production facilities, inability to obtain or delays
in obtaining fourth party, including AOAC, or required government approvals, the ability to meet increased market demand, competition, protection of
intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDI's public filings with the U.S.
Securities and Exchange Commission.
# # #